TY - JOUR
T1 - A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease
T2 - The Baltimore Longitudinal Study of Aging
AU - Kawas, Claudia
AU - Resnick, S.
AU - Morrison, A.
AU - Brookmeyer, R.
AU - Corrada, M.
AU - Zonderman, A.
AU - Bacal, C.
AU - Donnell Lingle, D.
AU - Metter, E.
PY - 1997/6
Y1 - 1997/6
N2 - Previous reports have suggested that estrogen replacement therapy (ERT) in women may exert a protective effect on their risk of developing Alzheimer's disease (AD). We investigated this relationship in the Baltimore Longitudinal Study of Aging (BLSA), a prospective multidisciplinary study of normal aging conducted by the National Institute on Aging. The sample consisted of 472 post-or perimenopausal women followed for up to 16 years in the BLSA. We documented ERT prospectively at each BLSA visit, and we categorized women who had used oral or transdermal estrogens at anytime as ERT users. We used Cox proportional hazards models with time-dependent covariates to estimate the relative risk of developing AD after ERT as compared with women who had not used estrogen replacement. Approximately 45% of the women in the cohort had used ERT, and we diagnosed 34 incident cases of AD (NINCDS/ADRDA criteria) during follow-up, including nine estrogen users. After adjusting for education, the relative risk for AD in ERT users as compared with nonusers was 0.46 (95% CI, 0.209-0.997), indicating a reduced risk of AD for women who had reported the use of estrogen. Our data did not show an effect for duration of ERT usage. Our finding offers additional support for a protective influence of estrogen in AD. Randomized clinical trials are necessary to confirm this association, which could have significant public health impact.
AB - Previous reports have suggested that estrogen replacement therapy (ERT) in women may exert a protective effect on their risk of developing Alzheimer's disease (AD). We investigated this relationship in the Baltimore Longitudinal Study of Aging (BLSA), a prospective multidisciplinary study of normal aging conducted by the National Institute on Aging. The sample consisted of 472 post-or perimenopausal women followed for up to 16 years in the BLSA. We documented ERT prospectively at each BLSA visit, and we categorized women who had used oral or transdermal estrogens at anytime as ERT users. We used Cox proportional hazards models with time-dependent covariates to estimate the relative risk of developing AD after ERT as compared with women who had not used estrogen replacement. Approximately 45% of the women in the cohort had used ERT, and we diagnosed 34 incident cases of AD (NINCDS/ADRDA criteria) during follow-up, including nine estrogen users. After adjusting for education, the relative risk for AD in ERT users as compared with nonusers was 0.46 (95% CI, 0.209-0.997), indicating a reduced risk of AD for women who had reported the use of estrogen. Our data did not show an effect for duration of ERT usage. Our finding offers additional support for a protective influence of estrogen in AD. Randomized clinical trials are necessary to confirm this association, which could have significant public health impact.
UR - http://www.scopus.com/inward/record.url?scp=0030748719&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030748719&partnerID=8YFLogxK
U2 - 10.1212/WNL.48.6.1517
DO - 10.1212/WNL.48.6.1517
M3 - Article
C2 - 9191758
AN - SCOPUS:0030748719
SN - 0028-3878
VL - 48
SP - 1517
EP - 1521
JO - Neurology
JF - Neurology
IS - 6
ER -